SPRY
NASDAQARS Pharmaceuticals Inc.
News25/Ratings12
Price$5.74+0.32 (+5.90%)
01:30 PM07:45 PM
News · 26 weeks46+100%
2026-03-012026-08-23
Mix2990d
- Insider14(48%)
- SEC Filings9(31%)
- Other4(14%)
- Earnings2(7%)
Latest news
25 items- SECSEC Form 144 filed by ARS Pharmaceuticals Inc.144 - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
- SECSEC Form 144 filed by ARS Pharmaceuticals Inc.144 - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
- SECSEC Form 144 filed by ARS Pharmaceuticals Inc.144 - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
- INSIDERSEC Form 3 filed by new insider Smith Margaret Ekins3 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- SECSEC Form 10-Q filed by ARS Pharmaceuticals Inc.10-Q - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
- SECARS Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
- PRARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results$26.2 million in U.S. neffy® net product revenue in Q2 2026; total U.S. epinephrine market share for Type 1 allergies of 5% and 8% share within field-targeted accounts Commercial investment realigned toward targeted provider engagement, significantly reducing total operating expenses for 2H 2026 and supporting an expected path to cash flow breakeven by the end of 2027 Commercial operations strengthened with appointment of Meg Smith as Chief Commercial Officer and completed expansion of field sales organization Interim data from Phase 2b trial in chronic spontaneous urticaria (CSU) expected in Q1 2027; no FDA-approved on-demand treatment currently exists for acute CSU flares Conference c
- PRARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial ResultsSAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Thursday, August 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. During the call, Donn Casale, President and Chief Executive Officer, will outline the Company’s updated strategic priorities and report second quarter 2026 financial results. Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, pleas
- SECSEC Form 8-K filed by ARS Pharmaceuticals Inc.8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ARS Pharmaceuticals Inc.SCHEDULE 13G/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
- SECSEC Form 8-K filed by ARS Pharmaceuticals Inc.8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
- PRARS Pharmaceuticals Announces CEO SuccessionRichard Lowenthal, Chief Executive Officer, Transitioning following More than a Decade of Leadership Since Co-Founding the Company Donn Casale, President, Appointed Chief Executive Officer and Director SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect against allergic reactions that could lead to anaphylaxis, today announced a CEO succession, in which co-founder and CEO Richard Lowenthal will no longer serve as an employee and officer of the company effective July 6, 2026. The Board has appointed Donn Casale, currently President, as CEO and Dire
- INSIDERSEC Form 4 filed by President Casale Donn4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- INSIDERSEC Form 4 filed by Director Ra Capital Management, L.P.4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- INSIDERSEC Form 4 filed by Director Dadoo Rajeev4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- INSIDERSEC Form 4 filed by Director Shah Pratik4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- INSIDERSEC Form 4 filed by Director Kelly Michael4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- INSIDERSEC Form 4 filed by Director Schneider Phillip M4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- INSIDERSEC Form 4 filed by Director Thompson Peter A.4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- INSIDERSEC Form 4 filed by Director Islam Saqib4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- INSIDERSEC Form 4 filed by Director Shawver Laura4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- INSIDERSEC Form 4 filed by Director Saunders Brent L4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- SECSEC Form 8-K filed by ARS Pharmaceuticals Inc.8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
- PRARS Pharmaceuticals Provides Commercial and Financial UpdatesNo new commercial formulary additions or coverage decisions issued for neffy (epinephrine nasal spray) in the July 1, 2026 cycle; company to continue payer discussions for potential future inclusion Total 2026 cash-based operating expenses, excluding COGS, lowered to $248 million, reflecting lower second-half spending and continued investment disciplineCompany reaffirms neffy base business supports a path to cash-flow breakeven in 2027 Phase 2b chronic spontaneous urticaria (CSU) program interim data readout expected Q4 2026 SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and thei
- INSIDERChief Commercial Officer Karas Eric exercised 25,000 shares at a strike of $1.50 and sold $250,000 worth of shares (25,000 units at $10.00) as part of a pre-agreed trading plan (SEC Form 4)4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
SPRY FAQ
6 questionsWhere does SPRY stock trade?
ARS Pharmaceuticals Inc. (SPRY) is listed on NASDAQ.What sector and industry is SPRY in?
ARS Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did ARS Pharmaceuticals Inc. go public?
ARS Pharmaceuticals Inc. (SPRY) completed its IPO in 2020.What are analysts saying about SPRY?
ARS Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Northland Capital: Outperform with a $2500.00 price target on 2026-04-09. Recent price targets range from $2000.00 to $4000.00.What companies are similar to SPRY?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SPRY side-by-side with any of them on Quantisnow.How can I track SPRY on Quantisnow?
Quantisnow aggregates ARS Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SPRY to receive live email and push alerts on every new disclosure.